AU:NOX Stock Latest News
Company AnnouncementsNoxopharm Proposes Securities Purchase Plan Issue1d agoNOX
Company AnnouncementsNoxopharm Proposes Issue of 625,000 Options1d agoNOX
Company AnnouncementsNoxopharm Advances Lupus and Immuno-Oncology Programs2d agoNOX
Company AnnouncementsNoxopharm Details Proposed Placement of Shares and Options2d agoNOX
Company AnnouncementsNoxopharm Proposes Placement of Shares and Options2d agoNOX
Company AnnouncementsNoxopharm Raises Funds to Advance Sofra Pipeline2d agoNOXCompany AnnouncementsNoxopharm Seeks Voluntary Suspension Ahead of Capital Raising Announcement6d agoNOX
Company AnnouncementsFDA feedback de-risks Noxopharm’s SOF-SKN Phase II trial plans3w agoNOX
Company AnnouncementsNoxopharm narrows loss as Sofra platform advances through trials, partnerships and new CEO1M agoNOX
Company AnnouncementsNoxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market1M agoNOX
Company AnnouncementsNoxopharm outlines precision therapy pipeline and clarifies trial links2M agoNOX
Company AnnouncementsNoxopharm’s SOF-SKN Trial Completion: Early Safety Milestone for a New Lupus Skin Therapy2M agoNOXCompany AnnouncementsNoxopharm’s Sofra Oligos Show Promise in Reducing mRNA Vaccine Reactogenicity2M agoNOX
Company AnnouncementsNoxopharm Preclinical Data Bolsters Sofra Immuno-Oncology Platform2M agoNOX
Company AnnouncementsNoxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy3M agoNOX
Company AnnouncementsNoxopharm advances Sofra platform as SOF-SKN nears FDA milestone3M agoNOX- Company AnnouncementsNoxopharm moves SOF-SKN toward U.S. FDA pathway to boost autoimmune portfolio4M agoNOX
Company AnnouncementsNoxopharm Sofra Platform Backed in $1m Grant for Childbirth Injury Treatment4M agoNOXCompany AnnouncementsNoxopharm unveils human-like TLR8 model to accelerate cancer immunotherapy program4M agoNOX